American Academy of Neurology Conference: Safety and efficacy of ORM-12741 on cognitive and behavioural symptoms in patients with Alzheimerâ€™s disease: A randomized, double-blind, placebo-controlled, parallel group, multicenter, proof-of-concept 12-week study.
Researchers have found a potential new treatment for Alzheimerâ€™s, ORM-12741, may improve some memory problems when used in combination with existing treatments. The results of a phase 2 trial of the drug are to be presented at the American Academy of Neurology annual meeting in March 2013.
The study involved 100 people with moderate stage Alzheimerâ€™s disease, who received a twice daily dose of either 30-60mg or 100-200mg of either ORM-12741 or a placebo. The treatment was continued for 12 weeks alongside cholinesterase inhibitors â€“ existing approved drugs that work to help with the symptoms of Alzheimerâ€™s. Some of the participants were also prescribed memantine, which is also designed to help with some of the diseaseâ€™s symptoms.
The participants were given a series of tests to assess their memory and thinking skills at the beginning and the end of the study. The results showed those who were taking ORM-12741 alongside their usual medication improved their scores on memory tests by 4%, while those taking the placebo had worsened by 33%.
Dr Simon Ridley, Head of Research at Alzheimerâ€™s Research UK, the UKâ€™s leading dementia research charity, said:
â€œThis clinical trial has reported some early, mixed results and itâ€™s important to note that this was a very small study that has yet to be published in full. This trial did not test how effective ORM-12741 was when used alone, and it remains to be seen how long its effects might last. We now need to see large-scale, long-term clinical trials to fully explore this treatmentâ€™s potential benefits for people with Alzheimerâ€™s.
â€œA drug that could provide more effective relief from the symptoms of Alzheimerâ€™s could have a real impact on peopleâ€™s lives, but we still lack a treatment that can tackle the underlying disease process. With half a million people living with Alzheimerâ€™s in the UK, and that number rising, research to find ways of stopping the disease in its tracks must continue.â€
This material has been published with the kind permission of Alzheimer Research UK.
© 2013, City Connect News. Copyright Notice & Disclaimer are below.